Board

Annexon’s Board of Directors is comprised of accomplished leaders in global biotechnology and the pharmaceutical industry, with expertise in governance, research, development and commercialization. The Board plays a central role in guiding the company towards the rapid advancement of our novel product pipeline.

William (Bill) Young, Board Chair

Industry executive & Board member

Mr. Young joined Clarus Ventures in 2010 as a Venture Partner from Monogram Biosciences, a leader in personalized medicine, where he served as chief executive officer from 1999 through to the sale of the company to LabCorp in 2009. Mr. Young currently serves on the Board of Directors of Vertex (NASDAQ: VRTX) and is the lead director at Theravance (NASDAQ:TBPH). Previously he was Chairman of the Board of Biogen IDEC (NASDAQ: BIIB). Prior to Monogram, he was at Genentech since 1980 in positions of increasing responsibility, including chief operating officer with responsibility for all of the biotechnology company’s development, operations and commercial functions. Prior to Genentech, Mr. Young was at Eli Lilly and Company for fourteen years.

Mr. Young received his bachelor’s degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his leadership in research, development and manufacturing of recombinant proteins using recombinant DNA technology.

Doug Love, Esq, Board Member

PRESIDENT & CEO, ANNEXON BIO

Mr. Love joined Annexon Biosciences as President and Chief Executive Officer in December 2014 with extensive business and legal leadership experience in biotech. He previously served as Head of Operations for Elan Pharmaceuticals. There, Mr. Love led the Tysabri® multiple sclerosis franchise, helping to propel it to nearly $2 billion in annual sales. He also led Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson for $1 billion plus milestones and royalties, as well as Elan’s global Commercial, Medical Affairs ad Alliance Management groups. Mr. Love is a corporate attorney by training, and prior to joining Elan, served as an associate at the law firm Orrick, Herrington & Sutcliffe, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech Inc., where he led the BioOncology Healthcare Law Group and launched several blockbuster programs. Mr. Love holds a J.D. with great distinction from McGeorge School of Law, Sacramento, CA, and a B.S. in business administration from the University of Southern California.

Campbell Murray, MD, Board Member

MANAGING DIRECTOR, NOVARTIS VENTURE FUND

Dr. Campbell Murray is a Managing Director at Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects. Campbell is a New Zealand-trained physician and worked as a Medical House Officer at Auckland Hospital. He is a Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio, Annexon, BioNano Genomics, Galera, ImaginAb and Neurovance.

Muneer Satter, Board Member

SATTER INVESTMENT MANAGEMENT

Muneer A. Satter is the Founder and Managing Partner of Satter Medical Technology Partners, L.P. since 2016 and Chairperson of Satter Investment Management LLC since 2012; he also manages the Satter Foundation. Prior to Satter Investment Management, Mr. Satter was a partner at Goldman Sachs where he spent 24 years in various roles, most recently as the Global Head of the Mezzanine Group in the Merchant Banking Division, where he raised and managed over $30 billion of assets. Mr. Satter is a member, and former co-Chairperson, of the Board of Directors of Linq3 Technologies, LLC. Mr. Satter also serves as Chairman of the Boards of Directors of Aerpio Pharmaceuticals, Inc. Akebia Therapeutics and Restorsea Holdings, LLC. He also serves as Vice Chairperson of Goldman Sachs Foundation and GS Gives, is a director of the Navy SEAL Foundation, a director of World Business Chicago, is on the Board of Advisors of the American Enterprise Institute and is on the Board of Trustees of Northwestern University, where he is Chairperson of the Finance Committee. Mr. Satter received a B.A. in economics from Northwestern University, a J.D. from Harvard Law School and an M.B.A. from Harvard Business School.

Emmett Cunningham, MD, PhD, MPH, Board Member

PARTNER, CLARUS VENTURES

Dr. Cunningham joined Clarus Ventures in 2006. He is currently a Partner at Clarus. Prior to joining Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc (NYSE: PFE), where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology.

Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 300 publications. He is Director of the Uveitis Service at California Pacific Medical Center, Adjunct Clinical Professor of Ophthalmology at Stanford University, and a Research Associate at The Francis I. Proctor Foundation, UCSF School of Medicine. Dr. Cunningham was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University and a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute. He completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF and The Francis I. Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital in London, and a fellowship in public health ophthalmology with Prof. Alfred Sommer at the Wilmer Eye Institute in Baltimore.

Dr. Cunningham represents Clarus on the Board of Directors of Graybug Vision, Restoration Robotics, and SFJ Pharmaceuticals Group.

Carol Gallagher, PharmD, Board Member

Partner, New Enterprise Associates, Inc.

Carol Gallagher joined NEA in October, 2014. She is primarily focused on making biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with nearly 30 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards. From 2008-2011, Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG.

Dr. Gallagher currently serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Metacrine, PIONYR Immunotherapeutics, Cleave Biosciences, AnaptysBio, and Xoc Pharmaceuticals.

Ricky Sun, PhD, Board Member

Partner, BAIN CAPITAL LIFE SCIENCES

Dr. Sun joined Bain Capital Life Sciences in 2016. He is currently a member of the Board of Directors of Arcutis. Previously he also served as a board observer for Replimune (Nasdaq: REPL).

Prior to joining Bain Capital, from 2013 to 2016, he was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group in Chicago and worked as a pharmaceuticals equity research analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceutical where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome.

Dr. Sun received a PhD degree in Chemistry and Chemical Biology from Harvard University and was an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School.  He also received an MBA from New York University Stern School of Business, where he was a Mildred Elperin Scholar.  He graduated summa cum laude from Berea College with a BA in chemistry.

Thomas G. Wiggans, Independent Board Member

Founder & CEO, Dermira

Tom Wiggans co-founded Dermira in 2010 and is the Company’s Chief Executive Officer and Chairman of the board of directors. He brings over 30 years of experience in specialty pharma and 18 years of experience in dermatology. Prior to founding Dermira, he served as Chairman of the board of directors and Chief Executive Officer of Peplin, Inc. until Peplin’s acquisition by LEO Pharma A/S in 2009. Previously, he served as Chairman of the board of directors and Chief Executive Officer of Connetics Corporation until Connetics was acquired by Stiefel Laboratories, Inc. in 2006. Prior to Connetics, he served as President and Chief Operating Officer of CytoTherapeutics Inc., and in various management positions at Ares-Serono S.A., including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. He began his career with Eli Lilly and Company.

Mr. Wiggans has served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx Pharmaceuticals, Inc., until its acquisition by Amgen in 2013, Sangamo Biosciences, Inc. and Somaxon Pharmaceuticals, Inc.

In addition, Mr. Wiggans is a member of the board of directors of Biotechnology Innovation Organization, a non-profit educational organization, and is a member of the board of trustees of the University of Kansas Endowment Association. He holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.

Arnon Rosenthal, PhD, Co-founder, Board Observer

Co-Founder & CEO, Alector

Arnon Rosenthal received his PhD from the Hebrew University Jerusalem, Israel, and then conducted a postdoctoral fellowship at Genentech, Inc. Following his postdoc, he was appointed to a scientist position at Genentech Inc., and was later promoted to a senior scientist and then to staff scientist and permanent member of Genentech Research Review Committee.

Dr. Rosenthal is co-founder of Rinat Neuroscience, a privately-held company that discovered and developed novel medicines for neurodegenerative, neuroendocrine and pain disorders, where he also served as President, board member and CSO. Rinat was acquired by Pfizer with several drugs in clinical development, including Tanezumab which is currently in Phase 3 for multiple pain indications, PF-04360365 which entered Phase 2 for Alzheimer’s disease and RN-307 which entered the clinic for migraine.

Dr. Rosenthal is also co-founder, President and CEO of Alector LLC, a privately held biotechnology company focused on the discovery and development of novel therapies for Alzheimer’s disease and other forms of dementia. Dr. Rosenthal is a visiting professor of the Department of Anatomy at the University of California San Francisco and a member of the scientific advisory boards of Simons Foundation, Autism Research Initiative and the Myelin Repair Foundation. He has co-authored 108 scientific publications and over 380 issued patents and applications.